Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company develops products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. The company's product portfolio includes EP-104IAR, which is in Phase III clinical trial for the treatment of knee osteoarthritis.
Its portfolio also includes EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis, and EP-104, which is under preclinical studies for the treatment of gastrointestinal tract, such as eosinophilic esophagitis. Incorporated in 2011 and headquartered in Victoria, Canada, Eupraxia Pharmaceuticals was formerly known as Plaza Capital Partners Inc. before rebranding in May 2012.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing products for therapeutic areas with significant unmet medical need. Its core technology is the proprietary Diffusphere platform, which optimizes drug delivery to improve efficacy and safety. The company’s lead product candidate is EP-104IAR, currently in Phase III clinical trials for the treatment of knee osteoarthritis. Additionally, EP-104GI is in Phase II trials for eosinophilic esophagitis, and EP-104 is under preclinical studies for gastrointestinal conditions such as eosinophilic esophagitis. Eupraxia aims to address chronic inflammatory and pain conditions through targeted, sustained-release therapies.
Where is Eupraxia Pharmaceuticals listed and what currency does it trade in?
Eupraxia Pharmaceuticals Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol EPRX. Its securities trade in U.S. dollars (USD). The company is headquartered in Victoria, Canada, but its shares are available to investors on the U.S. exchange, providing access to a broad base of international investors.
What sector and industry does Eupraxia Pharmaceuticals operate in?
Eupraxia Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, particularly those leveraging its Diffusphere drug delivery technology. The company targets inflammatory and pain-related conditions, such as knee osteoarthritis and eosinophilic esophagitis, which are areas with high unmet medical need.
Where is Eupraxia Pharmaceuticals headquartered and what is its history?
Eupraxia Pharmaceuticals Inc. is headquartered in Victoria, Canada. The company was incorporated in 2011 and was formerly known as Plaza Capital Partners Inc. before rebranding to its current name in May 2012. Since then, it has focused on advancing its pipeline of product candidates, all based on its Diffusphere technology platform, to address chronic inflammatory diseases.
What are the main product candidates in Eupraxia Pharmaceuticals' pipeline?
Eupraxia Pharmaceuticals' pipeline is centered on its Diffusphere drug delivery technology. The lead candidate, EP-104IAR, is in Phase III clinical trials for knee osteoarthritis, aiming to provide sustained pain relief. EP-104GI is in Phase II trials for eosinophilic esophagitis, a chronic inflammatory condition of the esophagus. Additionally, EP-104 is in preclinical development for gastrointestinal disorders, including eosinophilic esophagitis. These candidates are designed to improve patient outcomes by optimizing drug release and targeting specific tissues.